Cyclacel Pharmaceuticals Stock Today
| CYCC Stock | USD 2.30 0.51 28.49% |
Performance0 of 100
| Odds Of DistressOver 80
|
Cyclacel Pharmaceuticals is trading at 2.30 as of the 24th of April 2024, a 28.49 percent up since the beginning of the trading day. The stock's open price was 1.79. Cyclacel Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Cyclacel Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2024 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of May 2004 | Category Healthcare | Classification Health Care |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.. The company has 1.32 M outstanding shares of which 24.34 K shares are currently shorted by private and institutional investors with about 0.62 trading days to cover. More on Cyclacel Pharmaceuticals
Moving against Cyclacel Stock
| 0.73 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.72 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.66 | ELYM | Eliem Therapeutics | PairCorr |
| 0.54 | XFOR | X4 Pharmaceuticals Earnings Call Next Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 9th of May 2024
Cyclacel Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cyclacel Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cyclacel Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Spiro Rombotis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Cyclacel Pharmaceuticals report their recommendations after researching Cyclacel Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Cyclacel Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Cyclacel Pharmaceuticals. The Cyclacel consensus assessment is calculated by taking the average forecast from all of the analysts covering Cyclacel Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Cyclacel Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Cyclacel Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Cyclacel Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cyclacel Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Cyclacel Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cyclacel Pharmaceuticals' financial leverage. It provides some insight into what part of Cyclacel Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cyclacel Pharmaceuticals (CYCC) is traded on NASDAQ Exchange in USA. It is located in 200 Connell Drive, Berkeley Heights, NJ, United States, 07922 and employs 16 people. Cyclacel Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cyclacel Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Cyclacel Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cyclacel Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.32 M outstanding shares of which 24.34 K shares are currently shorted by private and institutional investors with about 0.62 trading days to cover.
Cyclacel Pharmaceuticals currently holds about 29.08 M in cash with (16.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cyclacel Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationCyclacel Pharmaceuticals shows 7.12 percent of its outstanding shares held by insiders and 16.73 percent owned by other corporate entities.
Check Cyclacel Ownership Details
Cyclacel Stock Price Odds Analysis
What are Cyclacel Pharmaceuticals' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Cyclacel Pharmaceuticals jumping above the current price in 90 days from now is about 50.0%. The Cyclacel Pharmaceuticals probability density function shows the probability of Cyclacel Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Cyclacel Pharmaceuticals has a beta of 0.652 suggesting as returns on the market go up, Cyclacel Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cyclacel Pharmaceuticals will be expected to be much smaller as well. Additionally, cyclacel Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Cyclacel Pharmaceuticals to move above the current price in 90 days from now is about 50.0 (This Cyclacel Pharmaceuticals probability density function shows the probability of Cyclacel Stock to fall within a particular range of prices over 90 days) .
Cyclacel Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Cyclacel Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cyclacel Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cyclacel Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2023-12-31 | 25.0 | |
| Signaturefd, Llc | 2023-12-31 | 20.0 | |
| Simplex Trading, Llc | 2023-09-30 | 17.0 | |
| Harbour Investments, Inc. | 2023-12-31 | 13.0 | |
| Qube Research & Technologies | 2023-12-31 | 3.0 | |
| State Street Corporation | 2023-12-31 | 0.0 | |
| Susquehanna International Group, Llp | 2023-09-30 | 0.0 | |
| Northern Trust Corp | 2023-12-31 | 0.0 | |
| Bridgeway Capital Management, Llc | 2023-09-30 | 0.0 | |
| Point72 Asset Management, L.p. | 2023-09-30 | 230 K | |
| Altium Capital Management, Lp | 2023-12-31 | 38 K |
Cyclacel Pharmaceuticals Historical Income Statement
Cyclacel Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Cyclacel's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Cyclacel Pharmaceuticals revenue and expense. Cyclacel Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Cyclacel Pharmaceuticals' Total Revenue is projected to decrease significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 408.4 K, whereas Depreciation And Amortization is forecasted to decline to about 29.4 K. View More FundamentalsCyclacel Stock Against Markets
Picking the right benchmark for Cyclacel Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cyclacel Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cyclacel Pharmaceuticals is critical whether you are bullish or bearish towards Cyclacel Pharmaceuticals at a given time. Please also check how Cyclacel Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cyclacel Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
Cyclacel Pharmaceuticals Corporate Directors
Cyclacel Pharmaceuticals corporate directors refer to members of a Cyclacel Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Cyclacel Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Cyclacel Pharmaceuticals' board members must vote for the resolution. The Cyclacel Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Gill Christie | Director Resources | Profile | |
| Samuel Barker | Director | Profile | |
| Gregory Hradsky | Independent Director | Profile | |
| John Banham | Independent Director | Profile |
How to buy Cyclacel Stock?
Before investing in Cyclacel Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Cyclacel Pharmaceuticals. To buy Cyclacel Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Cyclacel Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Cyclacel Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Cyclacel Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Cyclacel Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Cyclacel Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Cyclacel Stock please use our How to Invest in Cyclacel Pharmaceuticals guide.
Already Invested in Cyclacel Pharmaceuticals?
The danger of trading Cyclacel Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cyclacel Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cyclacel Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cyclacel Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.Note that the Cyclacel Pharmaceuticals information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Cyclacel Stock analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Cyclacel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (26.75) | Revenue Per Share 0.494 | Return On Assets (0.86) | Return On Equity (2.73) |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.